Alphatec Spine, Inc. Enters Agreement with International Spinal Innovations, LLC

* License bolsters intellectual property position surrounding a stand-alone ALIF
device with single step insertion and fixation to reduce procedure time and cost
* Alphatec Spine to launch stand-alone ALIF product in the U.S. and Europe in
2010

CARLSBAD, Calif.--(Business Wire)--
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine,
Inc., a medical device company that designs, develops, manufactures and markets
products for the surgical treatment of spine disorders, with a focus on treating
conditions related to the aging spine, announced today that it has entered into
an agreement with International Spinal Innovations, LLC, pursuant to which
International Spinal Innovations will provide Alphatec Spine worldwide license
rights to intellectual property related to a stand-alone anterior lumbar
interbody fusion (ALIF) device.

The International Spinal Innovations license, combined with intellectual
property previously acquired from SpineVision S.A., will allow Alphatec Spine to
develop and commercialize a zero-profile, self-locking interbody device for both
ALIF and cervical procedures. Alphatec Spine expects to submit its stand-alone
ALIF device to the U.S. Food and Drug Administration (FDA) for a 510k clearance
in the first half of 2010. In addition, the Company anticipates launching the
stand-alone ALIF product initially in Europe under a CE mark in the first half
of 2010.

The 2009 interbody fusion market in the U.S. is estimated to be more than $950
million. The 2009 ALIF market represents the largest interbody segment in the
U.S. with an estimated market in 2009 exceeding $350 million.

"We are extremely pleased to have acquired this unique concept for stand-alone
interbody devices," said Dirk Kuyper, the Company`s President and CEO. Mr.
Kuyper added, "The zero-profile, single-action locking implant is a substantial
improvement over devices requiring screws or additional steps." Mr. Kuyper
continued, "This new technology license, combined with intellectual property
previously acquired from SpineVision S.A., will enable Alphatec Spine to
leverage a strong proprietary position in the largest segment of the interbody
market. Both hospitals and surgeons are attempting to reduce procedure time and
cost, and stand-alone implants that do not require supplemental posterior
fixation are a logical progression in providing more cost-effective alternatives
for patients, surgeons and hospitals."

"This stand-alone device will be unique in that it will be designed to be
inserted and locked into the superior and inferior vertebral endplates in a
single step," said J.P. Timm, the Company`s Vice President of Research &
Development. Mr. Timm continued, "The simple insertion and fixation will result
in a quicker procedure that should reduce the risk to the patient and cost to
the hospital."

About Alphatec Spine

Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec Holdings, Inc.
(Nasdaq:ATEC). Alphatec Spine is a medical device company that designs,
develops, manufactures and markets products for the surgical treatment of spine
disorders, primarily focused on the aging spine. The Company's mission is to
combine world-class customer service with innovative, surgeon-driven design that
will help improve the aging patient's quality of life. The Company is poised to
achieve its goal through new solutions for patients with osteoporosis, stenosis
and other aging spine deformities, improved minimally invasive products and
techniques and integrated biologics solutions. In addition to its U.S.
operations, The Company also markets its spine products in Europe. In Asia, the
Company markets a broad line of spine and orthopedic products through its
subsidiary, Alphatec Pacific, Inc.

Also visit the Aging Spine Center, www.agingspinecenter.com, a web-based
information portal for healthcare providers and patients regarding aging spine
disorders and their treatment. The Company is working with the National
Osteoporosis Foundation as well as other clinical portals that provide
peer-reviewed content, to populate the Aging Spine Center. The interactive
website will enable patients to review pertinent information about disorders
that affect the aging spine in an easy-to-understand format that includes
videos, graphics and questions that should be asked of caregivers. Medical
information will include published abstracts regarding the aging spine.

Forward Looking Statements

This press release may contain "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve risks and
uncertainty. Such statements are based on management's current expectations and
are subject to a number of risks and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. These forward-looking statements include, but are not limited to:
Alphatec Spine's ability to accelerate new product momentum, bring to market
differentiated products and commercialize its product pipeline. Alphatec Spine
cautions investors that there can be no assurance that actual results or
business conditions will not differ materially from those projected or suggested
in such forward-looking statements as a result of various factors, including,
but not limited to, the following: Alphatec Spine's ability to meet its 2009
financial guidance, the growth rate of the spine market related to aging and
elderly patients, uncertainty of success in developing new products or products
currently in Alphatec Spine's pipeline, including stand-alone ALIF products, and
those products that are intended to treat disorders prevalent in aging patients,
failure to achieve acceptance of Alphatec Spine's products, including
stand-alone ALIF products, by the surgeon community, failure to obtain FDA
clearance or approval for new products, or unexpected or prolonged delays in the
process, including without limitation stand-alone ALIF products, Alphatec
Spine's ability to develop and expand its business in the United States, Asia
and Europe, continuation of favorable third party payor reimbursement for
procedures performed using Alphatec Spine's products, unanticipated expenses or
liabilities or other adverse events affecting cash flow or Alphatec Spine's
ability to successfully control its costs or achieve profitability, uncertainty
of additional funding, Alphatec Spine's ability to compete with other competing
products and with emerging new technologies, product liability exposure, patent
infringement claims and claims related to Alphatec Spine's intellectual
property. Please refer to the risks detailed from time to time in Alphatec
Spine's SEC reports, including quarterly reports on Form 10-Q, reports on Form
8-K and annual reports on Form 10-K. Alphatec Spine disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise, unless required by law.

For more information:
Alphatec Spine, Inc.
Peter C. Wulff, Chief Financial Officer
760-494-6746
investorrelations@alphatecspine.com
or
Westwicke Partners
Lynn C. Pieper, 415-202-5678
lynn.pieper@westwicke.com

Copyright Business Wire 2009